Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease

Xiaochun Xiong,Naiyuan Wang,Yixiao Zhang,Wenchao Zhao,Ningning Pang,Kequan Fu,Nan Zhou,Xueyan Zhou,Dong Guo

DOI: https://doi.org/10.1021/acs.jmedchem.4c00217

IF: 8.039

2024-03-21

Journal of Medicinal Chemistry

Abstract:The dysregulated intracellular cAMP in the kidneys drives cystogenesis and progression in autosomal dominant polycystic kidney disease (ADPKD). Mounting evidence supports that vasopressin V(2) receptor (V(2)R) antagonism effectively reduces cAMP levels, validating this receptor as a therapeutic target. Tolvaptan, an FDA-approved V(2)R antagonist, shows limitations in its clinical efficacy for ADPKD treatment. Therefore, the pursuit of better-in-class V(2)R antagonists with an improved efficacy...

chemistry, medicinal